Literature DB >> 22155743

The MPTP neurotoxic lesion model of Parkinson's disease activates the apolipoprotein E cascade in the mouse brain.

D Domenger1, D Dea, L Theroux, L Moquin, A Gratton, J Poirier.   

Abstract

Apolipoprotein E (apoE) is recognized as a key actor in brain remodeling. It has been shown to increase after peripheral and central injury, to modulate reparative capacity in neurodegenerative conditions like Alzheimer's disease (AD) and to be associated with a number of other neurodegenerative diseases. This particular function of apoE has been postulated to underlie the robust association with risk and age at onset of AD. ApoE associations studies with Parkinson's disease (PD), the second most prevalent neurodegenerative disease, have generated contradictory results but associations with age at onset and dementia in PD stand out. We investigate here whether apoE is involved in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced degeneration that models PD-like deafferentation of the striatum in the mouse and participates in compensatory reinnervation mechanisms. We examined the modifications in gene expression and protein levels of apoE and its key receptors, the low density lipoprotein receptor (LDLR) and the LDLR-related protein (LRP), as well as the reactive astrocyte marker glial fibrillary acidic protein (GFAP) in different brain structures throughout the degenerative and reactive regenerative period. In the striatum, upregulations of GFAP, apoE and LRP mRNAs at 1 day post-treatment were associated with marked decreases in dopamine (DA) levels, loss in tyrosine hydroxylase protein content, as well as to a compensatory increase in dopaminergic metabolism. Subsequent return to near control levels coincided with indications of reinnervation in the striatum: all consistent with a role of apoE during the degenerative process and regenerative period. We also found that this cascade was activated in the hippocampus and more so than in the striatum, with a particular contribution of LDLR expression. The hippocampal activation did not correlate with substantial neurochemical reductions but appears to reflect local subtle alteration of DA metabolism and the regulation of plasticity-related event in this structure. This study provides first evidence of an activation of the apoE/apoE receptors cascade in a mouse model of PD, specifically in the MPTP-induced deafferentation of the striatum. Results are also quite consistent with the postulated role of apoE in brain repair but, raise the issue of possible lesion- and region-specific alterations in gene expression.
Copyright © 2011. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22155743     DOI: 10.1016/j.expneurol.2011.11.031

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  12 in total

Review 1.  Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis.

Authors:  Sharawan Yadav; Anubhuti Dixit; Sonal Agrawal; Ashish Singh; Garima Srivastava; Anand Kumar Singh; Pramod Kumar Srivastava; Om Prakash; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2012-06-27       Impact factor: 5.590

2.  MPTP-induced changes in hippocampal synaptic plasticity and memory are prevented by memantine through the BDNF-TrkB pathway.

Authors:  Guoqi Zhu; Junyao Li; Ling He; Xuncui Wang; Xiaoqi Hong
Journal:  Br J Pharmacol       Date:  2015-03-26       Impact factor: 8.739

3.  Understanding the links between cardiovascular disease and Parkinson's disease.

Authors:  Judy Potashkin; Xuemei Huang; Claudia Becker; Honglei Chen; Thomas Foltynie; Connie Marras
Journal:  Mov Disord       Date:  2019-09-04       Impact factor: 10.338

4.  Targeted deletion of GD3 synthase protects against MPTP-induced neurodegeneration.

Authors:  Y Akkhawattanangkul; P Maiti; Y Xue; D Aryal; W C Wetsel; D Hamilton; S C Fowler; M P McDonald
Journal:  Genes Brain Behav       Date:  2017-04-18       Impact factor: 3.449

Review 5.  Neurodegeneration in Parkinson's disease: interactions of oxidative stress, tryptophan catabolites and depression with mitochondria and sirtuins.

Authors:  George Anderson; Michael Maes
Journal:  Mol Neurobiol       Date:  2013-10-02       Impact factor: 5.590

6.  A single intramuscular injection of rAAV-mediated mutant erythropoietin protects against MPTP-induced parkinsonism.

Authors:  A Dhanushkodi; E O Akano; E E Roguski; Y Xue; S K Rao; S G Matta; T S Rex; M P McDonald
Journal:  Genes Brain Behav       Date:  2012-11-28       Impact factor: 3.449

7.  A highly tunable dopaminergic oscillator generates ultradian rhythms of behavioral arousal.

Authors:  Ian D Blum; Lei Zhu; Luc Moquin; Maia V Kokoeva; Alain Gratton; Bruno Giros; Kai-Florian Storch
Journal:  Elife       Date:  2014-12-29       Impact factor: 8.140

8.  Complex network-driven view of genomic mechanisms underlying Parkinson's disease: analyses in dorsal motor vagal nucleus, locus coeruleus, and substantia nigra.

Authors:  Beatriz Raposo Corradini; Priscila Iamashita; Edilaine Tampellini; José Marcelo Farfel; Lea Tenenholz Grinberg; Carlos Alberto Moreira-Filho
Journal:  Biomed Res Int       Date:  2014-11-26       Impact factor: 3.411

9.  Effect of Vitamin D in HN9.10e Embryonic Hippocampal Cells and in Hippocampus from MPTP-Induced Parkinson's Disease Mouse Model.

Authors:  Samuela Cataldi; Cataldo Arcuri; Stéphane Hunot; Carmen Mecca; Michela Codini; Maria E Laurenti; Ivana Ferri; Elisabetta Loreti; Mercedes Garcia-Gil; Giovanna Traina; Carmela Conte; Francesco S Ambesi-Impiombato; Tommaso Beccari; Francesco Curcio; Elisabetta Albi
Journal:  Front Cell Neurosci       Date:  2018-02-07       Impact factor: 5.505

10.  Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study.

Authors:  Cristina Nombela; James B Rowe; Sophie E Winder-Rhodes; Adam Hampshire; Adrian M Owen; David P Breen; Gordon W Duncan; Tien K Khoo; Alison J Yarnall; Michael J Firbank; Patrick F Chinnery; Trevor W Robbins; John T O'Brien; David J Brooks; David J Burn; Roger A Barker
Journal:  Brain       Date:  2014-07-30       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.